Here are the S-3 shelf registrations from Sutro Biopharma, Inc. (STRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow STRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STRO filings page.
Sutro Biopharma, Inc. filed a shelf registration and preliminary prospectus permitting up to $300.0 million of securities and a prospectus supplement enabling an at-the-market program to sell up to $100.0 million of common stock through TD Securities (USA) LLC (TD Cowen) as agent or principal. The sales agreement contemplates negotiated transactions and at-the-market distributions, with compensation to TD Cowen of up to 3.0% of gross proceeds. The company reported 8,584,309 shares outstanding as of December 31, 2025, and the last reported sale price was $21.12 per share on March 19, 2026.